My Application Form Status

Check the status of your application form with Angel Broking.
Arq - The Hyper Intelligent Investment Engine By Angel Broking
Future Enterprises standalone net profit rises 615.37% in the June 2016 quarter

Future Enterprises standalone net profit rises 615.37% in the June 2016 quarter

Sep 14,2016

Net profit of Future Enterprises rose 615.37% to Rs 315.48 crore in the quarter ended June 2016 as against Rs 44.10 crore during the previous quarter ended June 2015. Sales declined 67.64% to Rs 921.19 crore in the quarter ended June 2016 as against Rs 2846.84 crore during the previous quarter ended June 2015.

ParticularsQuarter Ended
n++Jun. 2016Jun. 2015% Var.
Sales921.192846.84-68
OPM %24.969.91-
PBDT295.07184.1360
PBT142.3249.92185
NP315.4844.10615

Powered by Capital Market - Live News

Volumes jump at Divis Laboratories counter
Jul 10,2017

Divis Laboratories clocked volume of 58.14 lakh shares by 13:34 IST on BSE, a 64.05-times surge over two-week average daily volume of 91,000 shares. The stock rose 7.31% to Rs 729.85.

TeamLease Services notched up volume of 39,000 shares, a 49.52-fold surge over two-week average daily volume of 1,000 shares. The stock rose 2.52% to Rs 1,483.

MT Educare saw volume of 12.10 lakh shares, a 41.16-fold surge over two-week average daily volume of 29,000 shares. The stock rose 18.05% to Rs 78.50.

Sasken Technologies clocked volume of 1.64 lakh shares, a 24.85-fold surge over two-week average daily volume of 7,000 shares. The stock rose 7.16% to Rs 499.80.

D B Corp saw volume of 3.03 lakh shares, a 24.27-fold rise over two-week average daily volume of 12,000 shares. The stock fell 0.56% to Rs 381.60.

Powered by Capital Market - Live News

KCP Sugar & Industries Corporation gets reaffirmation in credit ratings
Jul 10,2017

KCP Sugar & Industries Corporation announced that CARE Ratings has reaffirmed its ratings in respect of bank facilities and fixed deposits as under -

Long term bank facilities (Rs 158.59 crore) - CARE A ; Stable
Short term bank facilities (Rs 6.50 crore) - CARE A1
Fixed Deposit programme (Rs 76.83 crore) - CARE A (FD); Stable

Powered by Capital Market - Live News

Fortis Healthcare gains as RBI hikes foreign investment ceiling
Jul 10,2017

Meanwhile, the S&P BSE Sensex was up 222.25 points or 0.71% at 31,582.88. The S&P BSE Mid-Cap index rose 58.28 points or 0.39% at 15,000.05.

On the BSE, 4.56 lakh shares were traded on the counter so far as against the average daily volumes of 9.83 lakh shares in the past one quarter. The stock had hit a high of Rs 163.90 and a low of Rs 162 so far during the day. The stock had hit a record high of Rs 230.90 on 3 May 2017 and a 52-week low of Rs 142.60 on 9 November 2016.

The stock had underperformed the market over the past one month till 7 July 2017, sliding 18.4% compared with the Sensexs 0.29% rise. The stock had also underperformed the market over the past one quarter, declining 14.87% as against the Sensexs 5.57% rise. The scrip had also underperformed the market over the past one year, declining 0.57% as against the Sensexs 15.29% rise.

The mid-cap company has equity capital of Rs 518.52 crore. Face value per share is Rs 10.

Fortis Healthcare reported consolidated net loss of Rs 37.52 crore in Q4 March 2017 compared with net loss of Rs 87.60 crore in Q4 March 2016. Net sales rose 5% to Rs 1123.43 crore in Q4 March 2017 over Q4 March 2016.

Fortis Healthcare is a leading integrated healthcare delivery service provider in India.

Powered by Capital Market - Live News

Graphite India recovers after recent slide
Jul 10,2017

Meanwhile, the S&P BSE Sensex was up 220.68 points, or 0.7% at 31,581.31. The S&P BSE Mid-Cap index was up 63.88 points, or 0.43% at 15,001.70.

On the BSE, 1.20 lakh shares were traded on the counter so far as against the average daily volumes of 96,444 shares in the past one quarter. The stock had hit a high of Rs 179.40 and a low of Rs 173.80 so far during the day. The stock had hit a record high of Rs 192 on 4 July 2017 and a 52-week low of Rs 70.10 on 30 September 2016.

The stock had outperformed the market over the past one month till 7 July 2017, advancing 45.66% compared with the Sensexs 0.29% rise. The scrip had also outperformed the market over the past one quarter advancing 43.2% as against the Sensexs 5.57% rise. The scrip had also outperformed the market over the past one year advancing 121.89% as against the Sensexs 15.29% rise.

The mid-cap company has equity capital of Rs 39.08 crore. Face value per share is Rs 2.

Shares of Graphite India had declined 7.35% in the preceding three trading sessions to settle at Rs 173.85 on Friday, 7 July 2017, from its closing price of Rs 187.65 on 4 July 2017.

Graphite Indias net profit spurted 117% to Rs 61.97 crore on 6.9% increase in net sales to Rs 373.39 crore in Q4 March 2017 over Q4 March 2016.

Graphite India is engaged in the manufacture of graphite electrodes including carbon and graphite specialty products.

Powered by Capital Market - Live News

Prakash Industries allots 5,29,979 equity shares
Jul 10,2017

Prakash Industries has allotted 5,29,979 Equity Shares of Rs 10 each on conversion of Foreign Currency Convertible Bonds (FCCBs). Consequent to the allotment, the paid up share capital of the Company has increased from Rs 148.95 crore to Rs 149.48 crore.

Powered by Capital Market - Live News

Sutlej Textiles and Industries announces demise of director
Jul 10,2017

Sutlej Textiles and Industries announced that Dr. Mahmoodur Rahman, our Director, passed away on 09 July 2017. In view of the above, he ceased to Director of the Company w.e.f. 09 July 2017.

Powered by Capital Market - Live News

Wipro allots 252,000 equity shares
Jul 10,2017

Wipro has allotted 252,000 equity shares under ADS Restricted Stock Unit Plan 2004 and 4,192 equity shares under Restricted Stock Unit Plan 2007 to the employees on 07 July 2017 pursuant to exercise of ESOPs.

Powered by Capital Market - Live News

20 Microns provides update on subsidiary - 20 Microns Nano Minerals
Jul 10,2017

20 Microns announced that its subsidiary, 20 Microns Nano Minerals has initiated process for going into its SME IPO for an aggregate amount of Rs 30 crore, subject to necessary consents / approvals for the same.

Powered by Capital Market - Live News

Ramco Systems wins Best Talent Management Solutions Enabling Technology Leadership Award
Jul 10,2017

Ramco Systems has clinched top honors at the annual 2017 Frost& Sullivan Excellence Awards, held in Singapore, earlier this month. The Company won the coveted Asia Pacific Talent Management Solutions Enabling Technology Leadership Award under the ICT category.

Powered by Capital Market - Live News

GST to boost MSMEs competitiveness, says study
Jul 10,2017

The Goods and Services Tax (GST) would boost the competitiveness of micro, small and medium enterprises (MSMEs), noted a recent joint study by ASSOCHAM- Ashvin Parekh Advisory Services (APAS).

n++From an MSME perspective, GST will bring in many positives compared to the current systems such as easy process of availing input credit, single point tax, elimination of cascading tax system, and simpler taxation,n++ said the study titled Emerging Mantras for Bankers-Borrowers, jointly conducted by ASSOCHAM and APAS.

The report also said that though there is no doubt that GST is aimed to increase the taxpayer base, and bring majorly MSMEs into its scope and that would put some burden of compliance and associated costs to them. But eventually, it will turn these MSMEs more competitive with a level playing field between large enterprises and them.

It also highlighted certain pros of GST on MSME sector viz., improved MSME market expansion, lower logistical overheads, boon for MSMEs dealing in sales and services, unified market and purchase of capital goods.

As part of cons of GST on MSME sector, the study highlighted - burden of lower threshold, no tax differentiation for luxury items and services, increase in cost of product, selective tax levying, burden of higher tax rate for service provider, excess working capital requirement, realignment of purchase and supply chain, dual control, high compliance burden and tax on advances, taxation under reverse charge for un-registered purchases, taxation on stock transfers and deemed supplies, time limit for return of goods sent on sale or return basis, condition of payment and filing of return for availing input tax credit and power to arrest and prosecution.

The study said that these pros offset the cons, as such the way forward while hopes rests with GST to boost the GDP growth and reduce the fiscal deficit.

Considering that all compliance procedures under GST n++ registration, payments, refunds and returns will now be carried out through online portals only and thus MSMEs need not worry about interacting with department officers for carrying out these compliances, which was earlier a cumbersome task.

Furthermore, Indian MSMEs would be able to compete with foreign competition coming from cheap cost centers such as China, Philippines, and Bangladesh.

The GST regime will usher in lower taxes, seamless input tax credit, logistics savings and market share swings from unorganized to organized players.

Powered by Capital Market - Live News

Zen Technologies enters into MoU with SCIS, University of Hyderabad
Jul 10,2017

Zen Technologies has entered into a memorandum of understanding with the School of Computer and Information Sciences (SCIS), University of Hyderabad (UoH) to bring in academy and industry collaboration. The MoU will be valid for a period of five years from the date of signing.

SCIS and Zen will nominate one representative each to coordinate and monitor all joint collaborative activities between the two institutions pertaining to research fellowship and doctoral programme, recognition of an external center, M.Tech programme in internship, joint research and development projects and joint events.

Zen Technologies has an innovative research and development division and is recognized as an in-house R&D unit by DSIR.

Powered by Capital Market - Live News

USFDA to lift Import Alert imposed of Divis Laboaratories Unit II
Jul 10,2017

Divis Laboratories has been informed by the USFDA that it will lift the Import Alert 99-32 imposed on the companys Unit-II at Visakhapatnam.

The USFDA has issued an Import Alert under clauses 99-32 and 66-40 in March of 2017 and a warning letter in May of 2017 for the Companys Vishakhapatnam facility.

Divis Laboratories has filed a detailed responses and given updates to the Form-483 and the warning letter within the stipulated time. Divis Laboratories, along with its external consultants, specialists and subject matter experts, has taken up appropriate remediation measures to address the concerns raised by USFDA. The company awaits further action from USFDA in this regard.

Powered by Capital Market - Live News

Biocon tumbles on observations by French health regulator
Jul 10,2017

Meanwhile, the S&P BSE Sensex was up 194.34 points or 0.62% at 31,554.97.

On the BSE, 6.49 lakh shares were traded on the counter so far as against the average daily volumes of 1.34 lakh shares in the past one quarter. The stock had hit a high of Rs 336 and a low of Rs 305 so far during the day. The stock had hit a record high of Rs 396 on 25 April 2017 and a 52-week low of Rs 229.66 on 19 July 2016.

The stock had outperformed the market over the past one month till 7 July 2017, advancing 1.27% compared with the Sensexs 0.29% rise. The stock had, however, underperformed the market over the past one quarter, declining 7.9% as against the Sensexs 5.57% rise. The scrip had outperformed the market over the past one year, surging 38.33% as against the Sensexs 15.29% rise.

The large-cap company has equity capital of Rs 300 crore. Face value per share is Rs 5.

In a stock exchange filing on Sunday, 9 July 2017, Biocon said the French inspecting authority (ANSM) conducted pre-approval inspection audits of the companys Bangalore drug substance and drug product sites related to the pending EMA Marketing Authorization Applications for Trastuzumab, Pegfilgrastim and related to Insulin Glargine (pen assembly only).

While there were no critical observations mentioned in the final report, ANSM notified Biocon that the receipt of a GMP compliance certificate for the drug product facility will require a follow up inspection from ANSM to verify implementation of the proposed corrective and preventive actions (CAPAs).

ANSM has reviewed the proposed CAPA plan and Biocon is progressing towards completion of the implementation of these CAPAs. Biocon, with its partner Mylan, will work with the French and European regulatory authorities with regard to the follow-up inspection of the drug product facility and the Marketing Authorization Applications with the goal of an early re-inspection.

ANSM has issued GMP compliance certificates for Biocons two drug substance manufacturing facilities in Bangalore. This is important as the drug substance manufacture is core to the production of the actual biologic product in GMP compliance, Biocon said in a statement.

On a consolidated basis, net profit of Biocon declined 61.7% to Rs 127.50 crore on 1.5% decline in net sales to Rs 919.20 crore in Q4 March 2017 over Q4 March 2016.

Biocon is Indias largest and fully-integrated, innovation-led biopharmaceutical company.

Powered by Capital Market - Live News

Diana Tea Company to hold AGM
Jul 10,2017

Diana Tea Company announced that the 106th Annual General Meeting (AGM) of the company will be held on 12 August 2017.

Powered by Capital Market - Live News

Fredun Pharmaceuticals to hold board meeting
Jul 10,2017

Fredun Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 12 July 2017.

Powered by Capital Market - Live News